Lv5
1510 积分 2025-04-25 加入
Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancer
17天前
已完结
A Highly Anticipated Selective Therapeutic Agent against CDK2: INX-315
19天前
已完结
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions
19天前
已完结
Discovery of AZD8421: A Potent CDK2 Inhibitor with Selectivity Against Other CDK Family Members and the Human Kinome
19天前
已完结
Cyclin E1 as a driver of oncogenesis; high grade serous ovarian cancer as an exemplar
19天前
已完结
Cyclin E1 as a driver of oncogenesis; high grade serous ovarian cancer as an exemplar
23天前
已完结
The evolving landscape of CDK2 inhibition in cancer: Therapeutic potential, clinical progress, and future directions
23天前
已完结
Selective CDK2 Degradation via Noncanonical Recruitment
23天前
已完结
Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy
23天前
已完结
皖公网安备34019202002308
